AIMS/HYPOTHESIS: Intramyocellular lipids (IMCL) accumulation is a classical feature of metabolic diseases. We hypothesised that IMCL accumulate mainly as a consequence of increased adiposity and independently of type 2 diabetes. To test this, we examined IMCL accumulation in two different models and four different populations of participants: muscle biopsies and primary human muscle cells derived from non-obese and obese participants with or without type 2 diabetes. The mechanism regulating IMCL accumulation was also studied. METHODS: Muscle biopsies were obtained from ten non-obese and seven obese participants without type 2 diabetes, and from eight non-obese and eight obese type 2 diabetic patients. Mitochondrial respiration, citrate synthase activity and both AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation were measured in muscle tissue. Lipid accumulation in muscle and primary myotubes was estimated by Oil Red O staining and fatty acid translocase (FAT)/CD36 localisation by immunofluorescence. RESULTS: Obesity and type 2 diabetes are independently characterised by skeletal muscle IMCL accumulation and permanent FAT/CD36 relocation. Mitochondrial function is not reduced in type 2 diabetes. IMCL accumulation was independent of type 2 diabetes in cultured myotubes and was correlated with obesity markers of the donor. In obese participants, membrane relocation of FAT/CD36 is a determinant of IMCL accumulation. CONCLUSIONS/ INTERPRETATION: In skeletal muscle, mitochondrial function is normal in type 2 diabetes, while IMCL accumulation is dependent upon obesity or type 2 diabetes and is related to sarcolemmal FAT/CD36 relocation. In cultured myotubes, IMCL content and FAT/CD36 relocation are independent of type 2 diabetes, suggesting that distinct factors in obesity and type 2 diabetes contribute to permanent FAT/CD36 relocation ex vivo.
AIMS/HYPOTHESIS: Intramyocellular lipids (IMCL) accumulation is a classical feature of metabolic diseases. We hypothesised that IMCL accumulate mainly as a consequence of increased adiposity and independently of type 2 diabetes. To test this, we examined IMCL accumulation in two different models and four different populations of participants: muscle biopsies and primary human muscle cells derived from non-obese and obeseparticipants with or without type 2 diabetes. The mechanism regulating IMCL accumulation was also studied. METHODS: Muscle biopsies were obtained from ten non-obese and seven obeseparticipants without type 2 diabetes, and from eight non-obese and eight obese type 2 diabeticpatients. Mitochondrial respiration, citrate synthase activity and both AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation were measured in muscle tissue. Lipid accumulation in muscle and primary myotubes was estimated by Oil Red O staining and fatty acid translocase (FAT)/CD36 localisation by immunofluorescence. RESULTS:Obesity and type 2 diabetes are independently characterised by skeletal muscle IMCL accumulation and permanent FAT/CD36 relocation. Mitochondrial function is not reduced in type 2 diabetes. IMCL accumulation was independent of type 2 diabetes in cultured myotubes and was correlated with obesity markers of the donor. In obeseparticipants, membrane relocation of FAT/CD36 is a determinant of IMCL accumulation. CONCLUSIONS/ INTERPRETATION: In skeletal muscle, mitochondrial function is normal in type 2 diabetes, while IMCL accumulation is dependent upon obesity or type 2 diabetes and is related to sarcolemmal FAT/CD36 relocation. In cultured myotubes, IMCL content and FAT/CD36 relocation are independent of type 2 diabetes, suggesting that distinct factors in obesity and type 2 diabetes contribute to permanent FAT/CD36 relocation ex vivo.
Authors: Susan L M Coort; Jodil Willems; Will A Coumans; Ger J van der Vusse; Arend Bonen; Jan F C Glatz; Joost J F P Luiken Journal: Mol Cell Biochem Date: 2002-10 Impact factor: 3.396
Authors: Barbara Ukropcova; Michele McNeil; Olga Sereda; Lilian de Jonge; Hui Xie; George A Bray; Steven R Smith Journal: J Clin Invest Date: 2005-07 Impact factor: 14.808
Authors: Veronic Bezaire; Clinton R Bruce; George J F Heigenhauser; Narendra N Tandon; Jan F C Glatz; Joost J J F Luiken; Arend Bonen; Lawrence L Spriet Journal: Am J Physiol Endocrinol Metab Date: 2005-10-11 Impact factor: 4.310
Authors: Matthew W Hulver; Jason R Berggren; Michael J Carper; Makoto Miyazaki; James M Ntambi; Eric P Hoffman; John P Thyfault; Robert Stevens; G Lynis Dohm; Joseph A Houmard; Deborah M Muoio Journal: Cell Metab Date: 2005-10 Impact factor: 27.287
Authors: D A Pan; S Lillioja; A D Kriketos; M R Milner; L A Baur; C Bogardus; A B Jenkins; L H Storlien Journal: Diabetes Date: 1997-06 Impact factor: 9.461
Authors: Arend Bonen; Michelle L Parolin; Gregory R Steinberg; Jorge Calles-Escandon; Narendra N Tandon; Jan F C Glatz; Joost J F P Luiken; George J F Heigenhauser; David J Dyck Journal: FASEB J Date: 2004-05-07 Impact factor: 5.191
Authors: Céline Aguer; Colin S McCoin; Trina A Knotts; A Brianne Thrush; Kikumi Ono-Moore; Ruth McPherson; Robert Dent; Daniel H Hwang; Sean H Adams; Mary-Ellen Harper Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191
Authors: G P Holloway; C J Chou; J Lally; T Stellingwerff; A C Maher; O Gavrilova; M Haluzik; H Alkhateeb; M L Reitman; A Bonen Journal: Diabetologia Date: 2011-03-26 Impact factor: 10.122
Authors: Yaqin Liang; Anna L Lang; Jian Zhang; Jing Chen; Kai Wang; Liya Chen; Juliane I Beier; Yan Qian; Lu Cai Journal: Chem Res Toxicol Date: 2018-05-10 Impact factor: 3.739